jakinibs
Jakinibs are a class of small-molecule medications that inhibit the activity of the Janus kinase (JAK) family, including JAK1, JAK2, JAK3, and TYK2, within the JAK-STAT signaling pathway. By blocking the phosphorylation of JAKs, they reduce activation of STAT transcription factors and downregulate the expression of various pro-inflammatory cytokines. Inhibitor selectivity varies, with some agents acting broadly on multiple JAKs and others targeting specific JAK family members, influencing therapeutic effects and safety profiles.
Jakinibs are used to treat a range of autoimmune and inflammatory conditions. Indications include rheumatoid arthritis,
Administration and monitoring vary by agent, but most jakinibs are taken orally, with some topical formulations
Safety considerations include an elevated risk of serious infections, herpes zoster, thromboembolic events, cytopenias, dyslipidemia, and